TMC207 becomes bedaquiline, a new anti-TB drug

Author： Palomino Juan Carlos   Martin Anandi  

Publisher： Future Medicine

ISSN： 1746-0913

Source： Future Microbiology, Vol.8, Iss.9, 2013-09, pp. : 1071-1080

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

By Matteelli Alberto   Carvalho Anna CC   Dooley Kelly E   Kritski Afranio  

Future Microbiology, Vol. 5, Iss. 6, 2010-06 ,pp. : 849-858

Future Medicine

Access to resources Recommend Favorite

Importance of improved TB diagnostics in addressing the extensively drug-resistant TB crisis

By Parrish Nicole   Carrol Karen  

Future Microbiology, Vol. 3, Iss. 4, 2008-08 ,pp. : 405-413

Future Medicine

Access to resources Recommend Favorite

A new resource for TB diagnostics developers

By Qin Zhi Zhen   Pai Madhukar  

Future Microbiology, Vol. 8, Iss. 12, 2013-12 ,pp. : 1507-1509

Future Medicine

Access to resources Recommend Favorite

Old foes, new challenges: syphilis, cholera and TB

By Stamm Lola V   Mudrak Benjamin  

Future Microbiology, Vol. 8, Iss. 2, 2013-02 ,pp. : 177-189

Future Medicine

Access to resources Recommend Favorite

Back to the future: host-targeted chemotherapeutics for drug-resistant TB

By Napier Ruth J   Shinnick Thomas M   Kalman Daniel  

Future Microbiology, Vol. 7, Iss. 4, 2012-04 ,pp. : 431-435

Future Medicine

Access to resources Recommend Favorite